These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 21575896

  • 1. Adalimumab for recurrent orbital myositis in Crohn's disease: report of a case with a 3-year follow-up.
    Hernández-Garfella ML, Gracia-García A, Cervera-Taulet E, García-Villanueva C, Montero-Hernández J.
    J Crohns Colitis; 2011 Jun; 5(3):265-6. PubMed ID: 21575896
    [No Abstract] [Full Text] [Related]

  • 2. Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature.
    Verma S, Kroeker KI, Fedorak RN.
    BMC Gastroenterol; 2013 Apr 04; 13():59. PubMed ID: 23556424
    [Abstract] [Full Text] [Related]

  • 3. Recurrent orbital myositis as an extra-intestinal manifestation of Crohn's disease.
    Pimentel R, Lago P, Pedroto I.
    J Crohns Colitis; 2012 Oct 04; 6(9):958-9. PubMed ID: 22704659
    [No Abstract] [Full Text] [Related]

  • 4. [The use of adalimumab in severe fistulising Crohn's disease].
    Bang UC, Nielsen AM.
    Ugeskr Laeger; 2008 Jun 16; 170(25):2256. PubMed ID: 18565318
    [Abstract] [Full Text] [Related]

  • 5. Fulminant Crohn's colitis: when only an antibody will do.
    Ng SC, Kamm MA.
    Inflamm Bowel Dis; 2007 Aug 16; 13(8):971-4. PubMed ID: 17427240
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab as therapy for fistulizing orofacial Crohn's disease.
    Doherty G, Kalachand R, Patchett S.
    Inflamm Bowel Dis; 2010 Feb 16; 16(2):184-5. PubMed ID: 19408321
    [No Abstract] [Full Text] [Related]

  • 7. Adalimumab for cutaneous metastatic Crohn's disease.
    Cury DB, Moss AC, Elias G, Nakao A.
    Inflamm Bowel Dis; 2010 May 16; 16(5):723-4. PubMed ID: 19728388
    [No Abstract] [Full Text] [Related]

  • 8. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
    Malesci A, Angelucci E, Bonifacio C, Sociale O, Omodei P, Repici A, Balzarini L, Danese S.
    Inflamm Bowel Dis; 2009 Jun 16; 15(6):814-5. PubMed ID: 18831523
    [No Abstract] [Full Text] [Related]

  • 9. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
    Jürgens M, Brand S, Filik L, Hübener C, Hasbargen U, Beigel F, Tillack C, Göke B, Ochsenkühn T, Seiderer J.
    Inflamm Bowel Dis; 2010 Oct 16; 16(10):1634-6. PubMed ID: 20027647
    [No Abstract] [Full Text] [Related]

  • 10. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
    Jałocha Ł, Wojtuń S, Wojtkowiak M, Błaszak A, Dyrla P, Gil J.
    Pol Merkur Lekarski; 2009 May 16; 26(155):491-2. PubMed ID: 19606707
    [Abstract] [Full Text] [Related]

  • 11. Duodenal Crohn's disease successfully treated with adalimumab.
    Tursi A.
    Endoscopy; 2011 May 16; 43 Suppl 2 UCTN():E22. PubMed ID: 21271523
    [No Abstract] [Full Text] [Related]

  • 12. Early postoperative recurrence of severe Crohn's disease, with colonic involvement and associated human cytomegalovirus infection, treated with oral valganciclovir and adalimumab.
    Sinagra E, Renna S, Mocciaro F, Olivo M, Cottone M, Orlando A.
    Inflamm Bowel Dis; 2011 Jun 16; 17(6):E43-4. PubMed ID: 21438099
    [No Abstract] [Full Text] [Related]

  • 13. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD, Richards R.
    Am J Gastroenterol; 2009 Mar 16; 104(3):792-3. PubMed ID: 19262532
    [No Abstract] [Full Text] [Related]

  • 14. Esophageal Crohn's disease treated successfully with adalimumab.
    Kwan LY, Conklin JL, Papadakis KA.
    Inflamm Bowel Dis; 2007 May 16; 13(5):639-40. PubMed ID: 17221856
    [No Abstract] [Full Text] [Related]

  • 15. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab.
    Quin A, Kane S, Ulitsky O.
    Nat Clin Pract Gastroenterol Hepatol; 2008 May 16; 5(5):278-81. PubMed ID: 18364718
    [Abstract] [Full Text] [Related]

  • 16. [Recommendations for patients with Crohn's disease starting treatment with adalimumab: a rapid guide].
    Cabriada JL, García Sánchez V, Gomollón F, Hinojosa J, López San Román A, Mendoza JL, Mínguez M, Ricart E, Saro C.
    Gastroenterol Hepatol; 2008 Dec 16; 31(10):693-7. PubMed ID: 19174086
    [No Abstract] [Full Text] [Related]

  • 17. Recurrent orbital myositis with radiological feature mimicking thyroid eye disease in a patient with Crohn's disease.
    Cheng S, Vu P.
    Orbit; 2009 Dec 16; 28(6):368-70. PubMed ID: 19929661
    [Abstract] [Full Text] [Related]

  • 18. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
    Gupta A, Pendyala P, Arora P, Sitrin MD.
    J Clin Gastroenterol; 2011 Mar 16; 45(3):e30-3. PubMed ID: 20975576
    [Abstract] [Full Text] [Related]

  • 19. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
    Ricart E, Ordás I, Panés J.
    Gut; 2012 Feb 16; 61(2):169-70. PubMed ID: 22068167
    [No Abstract] [Full Text] [Related]

  • 20. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
    Alkhouri N, Hupertz V, Mahajan L.
    Inflamm Bowel Dis; 2009 Jun 16; 15(6):803-6. PubMed ID: 18942748
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.